NCT04734262 2023-11-18
SPARK
Fudan University
Phase 2 Unknown
Clinical Trials
3 trialsNCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05104801 2021-11-04
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown